FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2168645087> ?p ?o ?g. }

• W2168645087 abstract "Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.In this 6-month, phase 3, randomized, placebo-controlled trial, 611 patients with inadequate response to disease-modifying anti-rheumatic drugs (DMARD-IR) were randomized 4:4:1:1 to receive: tofacitinib 5 mg BID or tofacitinib 10 mg BID for the duration of the study, or placebo for 3 months followed by tofacitinib 5 mg BID or tofacitinib 10 mg BID. Patient-reported outcomes (PROs) included: Patient Global Assessment of Disease Activity (PtGA); Patient Assessment of Pain (Pain); Health Assessment Questionnaire-Disability Index (HAQ-DI); Medical Outcomes Survey (MOS) Short Form-36 (SF-36); Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F); and MOS Sleep Scale. Time-to-event data (PtGA and Pain) were collected using an interactive voice response system daily diary (baseline through day 14).At month 3, tofacitinib 5 and 10 mg BID demonstrated statistically significant improvements versus placebo in PtGA (both p < 0.0001), Pain (both p < 0.0001), HAQ-DI (both p < 0.0001), SF-36 Physical (p < 0.0001) and Mental (p < 0.05 [5 mg BID] and p < 0.0001 [10 mg BID]), Component Summary scores and all domain scores (p < 0.05-p < 0.0001) and FACIT-F (both p < 0.0001). Statistically significant changes from baseline in MOS Sleep Scale were reported for 10 mg BID (p < 0.05). Benefits of tofacitinib treatment were rapid in onset and significant improvements were reported at week 2 for PtGA, Pain and HAQ-DI, and differentiation from baseline was seen as early as 3 days after treatment initiation for interactive voice response system (IVRS) PtGA and IVRS Pain. The numbers needed to treat for patients to report changes greater than or equal to the minimum clinically important difference in PtGA, Pain, HAQ-DI, SF-36 Physical Component Summary score and FACIT-F ranged between 4.0-6.1 (5 mg BID) and 3.2-5.0 (10 mg BID).Tofacitinib monotherapy in DMARD-IR patients resulted in statistically significant and clinically meaningful improvements in multiple PROs versus placebo at month 3, with sustained improvements over 6 months.Clinicaltrials.gov registration NCT00814307 , registered 22 December 2008." @default.
• W2168645087 created "2016-06-24" @default.
• W2168645087 creator A5006565253 @default.
• W2168645087 creator A5012283576 @default.
• W2168645087 creator A5014147030 @default.
• W2168645087 creator A5029796262 @default.
• W2168645087 creator A5034581240 @default.
• W2168645087 creator A5040449706 @default.
• W2168645087 creator A5046261111 @default.
• W2168645087 creator A5064863811 @default.
• W2168645087 date "2015-11-04" @default.
• W2168645087 modified "2023-10-14" @default.
• W2168645087 title "Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs" @default.
• W2168645087 cites W1041331430 @default.
• W2168645087 cites W1492940207 @default.
• W2168645087 cites W1829201716 @default.
• W2168645087 cites W1968025567 @default.
• W2168645087 cites W1974321634 @default.
• W2168645087 cites W1976591039 @default.
• W2168645087 cites W1978576762 @default.
• W2168645087 cites W1990105300 @default.
• W2168645087 cites W2014330392 @default.
• W2168645087 cites W2021866526 @default.
• W2168645087 cites W2026720490 @default.
• W2168645087 cites W2035320881 @default.
• W2168645087 cites W2038992287 @default.
• W2168645087 cites W2041499523 @default.
• W2168645087 cites W2045901968 @default.
• W2168645087 cites W2046744512 @default.
• W2168645087 cites W2069302785 @default.
• W2168645087 cites W2075648776 @default.
• W2168645087 cites W2101217991 @default.
• W2168645087 cites W2106216235 @default.
• W2168645087 cites W2108476653 @default.
• W2168645087 cites W2117642771 @default.
• W2168645087 cites W2120393706 @default.
• W2168645087 cites W2125793256 @default.
• W2168645087 cites W2129948300 @default.
• W2168645087 cites W2130240143 @default.
• W2168645087 cites W2132309748 @default.
• W2168645087 cites W2149189075 @default.
• W2168645087 cites W2149447280 @default.
• W2168645087 cites W2153414586 @default.
• W2168645087 cites W2161344815 @default.
• W2168645087 cites W2164858045 @default.
• W2168645087 cites W2166732840 @default.
• W2168645087 cites W2168242569 @default.
• W2168645087 cites W2413265834 @default.
• W2168645087 cites W4210768724 @default.
• W2168645087 cites W2186881202 @default.
• W2168645087 cites W2394545201 @default.
• W2168645087 doi "https://doi.org/10.1186/s13075-015-0825-9" @default.
• W2168645087 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4632359" @default.
• W2168645087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26530039" @default.
• W2168645087 hasPublicationYear "2015" @default.
• W2168645087 type Work @default.
• W2168645087 sameAs 2168645087 @default.
• W2168645087 citedByCount "50" @default.
• W2168645087 countsByYear W21686450872016 @default.
• W2168645087 countsByYear W21686450872017 @default.
• W2168645087 countsByYear W21686450872018 @default.
• W2168645087 countsByYear W21686450872019 @default.
• W2168645087 countsByYear W21686450872020 @default.
• W2168645087 countsByYear W21686450872021 @default.
• W2168645087 countsByYear W21686450872022 @default.
• W2168645087 countsByYear W21686450872023 @default.
• W2168645087 crossrefType "journal-article" @default.
• W2168645087 hasAuthorship W2168645087A5006565253 @default.
• W2168645087 hasAuthorship W2168645087A5012283576 @default.
• W2168645087 hasAuthorship W2168645087A5014147030 @default.
• W2168645087 hasAuthorship W2168645087A5029796262 @default.
• W2168645087 hasAuthorship W2168645087A5034581240 @default.
• W2168645087 hasAuthorship W2168645087A5040449706 @default.
• W2168645087 hasAuthorship W2168645087A5046261111 @default.
• W2168645087 hasAuthorship W2168645087A5064863811 @default.
• W2168645087 hasBestOaLocation W21686450871 @default.
• W2168645087 hasConcept C126322002 @default.
• W2168645087 hasConcept C142724271 @default.
• W2168645087 hasConcept C168563851 @default.
• W2168645087 hasConcept C1862650 @default.
• W2168645087 hasConcept C197934379 @default.
• W2168645087 hasConcept C198451711 @default.
• W2168645087 hasConcept C204787440 @default.
• W2168645087 hasConcept C27081682 @default.
• W2168645087 hasConcept C2776233030 @default.
• W2168645087 hasConcept C2777575956 @default.
• W2168645087 hasConcept C2778886723 @default.
• W2168645087 hasConcept C71924100 @default.
• W2168645087 hasConceptScore W2168645087C126322002 @default.
• W2168645087 hasConceptScore W2168645087C142724271 @default.
• W2168645087 hasConceptScore W2168645087C168563851 @default.
• W2168645087 hasConceptScore W2168645087C1862650 @default.
• W2168645087 hasConceptScore W2168645087C197934379 @default.
• W2168645087 hasConceptScore W2168645087C198451711 @default.
• W2168645087 hasConceptScore W2168645087C204787440 @default.
• W2168645087 hasConceptScore W2168645087C27081682 @default.
• W2168645087 hasConceptScore W2168645087C2776233030 @default.
• W2168645087 hasConceptScore W2168645087C2777575956 @default.
• W2168645087 hasConceptScore W2168645087C2778886723 @default.
• W2168645087 hasConceptScore W2168645087C71924100 @default.

• next